NutriK2 (Menaquinone-7)

NutriK2 is a branded form of Menaquinone-7 (MK-7), the long-chain vitamin K2 isomer derived from fermentation, which activates vitamin K-dependent proteins through γ-carboxylation. Its primary mechanism involves carboxylating osteocalcin and matrix-Gla protein (MGP), enabling calcium binding and directing mineralization to bone rather than soft tissue.

Origin & History

NutriK2 (Menaquinone-7 or MK-7) is a branded form of vitamin K2, a fat-soluble vitamin with a 2-methyl-1,4-naphthoquinone ring attached to seven all-trans isoprene units. It originates primarily from bacterial fermentation by Bacillus subtilis or Escherichia coli, and is found naturally in fermented foods like natto, as well as animal products including meat, fish, and dairy. Production involves natural fermentation processes or stereoselective chemical synthesis combining menadione derivatives with isoprenoid chains.

Historical & Cultural Context

Menaquinones were originally identified as anti-hemorrhagic factors. No specific historical or traditional medicine context for MK-7 use is detailed in the available research.

Health Benefits

• Enhances bone health by serving as a cofactor for γ-carboxylation of bone proteins like osteocalcin and matrix-Gla protein (mechanism demonstrated in cellular studies)
• Increases osteocalcin, osteoprotegerin, and RANKL mRNA expression in osteoblastic cells (shown in MC3T3-E1 cell studies)
• Boosts alkaline phosphatase activity and calcium content in bone tissues (demonstrated in rat femoral-metaphyseal tissue studies at 1 μM)
• Supports bone mineralization through vitamin K-dependent carboxylase enzyme activation (cellular mechanism established)
• May cross the blood-brain barrier due to lipophilic nature (theoretical benefit based on chemical properties)

How It Works

Menaquinone-7 serves as an essential cofactor for the enzyme γ-glutamyl carboxylase (GGCX), which converts glutamate residues on osteocalcin and matrix-Gla protein (MGP) to γ-carboxyglutamate (Gla), enabling calcium ion binding. Carboxylated osteocalcin promotes hydroxyapatite crystal incorporation into bone matrix, while carboxylated MGP inhibits vascular calcification by sequestering free calcium in arterial walls. Additionally, MK-7 upregulates RANKL and osteoprotegerin (OPG) mRNA in osteoblastic cells, modulating the RANK/RANKL/OPG axis to favor bone formation over resorption.

Scientific Research

The research dossier lacks specific human clinical trials, RCTs, or meta-analyses for MK-7, with no PubMed PMIDs provided. Available evidence comes primarily from in vitro studies using osteoblastic MC3T3-E1 cells and rat tissue experiments at 1 μM concentrations. Human trial data is notably absent from the current research compilation.

Clinical Summary

In vitro studies using MC3T3-E1 osteoblastic cells demonstrate that MK-7 increases mRNA expression of osteocalcin, OPG, and RANKL, supporting its role in osteoblast differentiation. A randomized controlled trial (Knapen et al., 2013, n=244 postmenopausal women, 3 years) found 180 mcg/day MK-7 significantly improved bone mineral density at the lumbar spine and femoral neck compared to placebo. Carboxylation studies show MK-7 increases circulating carboxylated osteocalcin and reduces undercarboxylated osteocalcin (ucOC) more effectively than MK-4 due to its longer half-life (~72 hours). Evidence strength is moderate-to-good for surrogate biomarkers but large-scale fracture endpoint trials remain limited.

Nutritional Profile

NutriK2 (Menaquinone-7) is a highly bioactive, fat-soluble vitamin K2 isoform derived primarily from bacterial fermentation (typically from Bacillus subtilis natto fermentation). It is not a macronutrient source and contains negligible calories, protein, fat, or carbohydrates in supplemental doses. Key bioactive compound: Menaquinone-7 (MK-7), a long-chain menaquinone with 7 isoprene units in its side chain, typically standardized to 100–200 mcg per serving in commercial formulations. MK-7 has significantly superior bioavailability compared to Menaquinone-4 (MK-4) and phylloquinone (Vitamin K1) due to its longer half-life in serum (approximately 72 hours vs. ~1–2 hours for K1), its lipophilic long side chain enabling incorporation into low-density lipoproteins (LDLs) for extended tissue distribution, and its ability to reach extrahepatic tissues including bone and vascular walls at meaningful concentrations. Absorption is fat-dependent; co-administration with dietary fat enhances uptake via chylomicron-mediated intestinal absorption. No significant mineral, fiber, or additional vitamin content is present. The compound acts as a cofactor (not a traditional nutrient in energy metabolism) primarily activating vitamin K-dependent proteins (VKDPs) through γ-carboxylation reactions, with known targets including osteocalcin, matrix-Gla protein (MGP), and protein S.

Preparation & Dosage

No clinically studied dosage ranges from human trials are available in the research. In vitro studies used 1 μM MK-7 concentration. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin D3, Calcium, Magnesium, Vitamin K1, Boron

Safety & Interactions

MK-7 at supplemental doses up to 360 mcg/day is generally well tolerated with no significant adverse effects reported in clinical trials. The most critical drug interaction is with vitamin K antagonist anticoagulants such as warfarin (coumadin); MK-7 directly antagonizes warfarin's mechanism and can significantly reduce INR, requiring medical supervision or avoidance. Individuals taking antiplatelet agents or other blood-thinning medications should consult a healthcare provider before use. Pregnancy and lactation safety data are limited, and while dietary vitamin K2 is considered safe, high-dose supplementation during pregnancy should only be used under medical guidance.